Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata.
Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We have the expertise to manufacture and package a wide range of pharmaceutical products, including oral films, creams, and lotions, for our contract licensees and customers.
“Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.”
Dan Barber
President and Chief Executive Officer
Our leadership
Our experienced Leadership Team and active Board of Directors bring deep industry expertise and a shared commitment to scientific innovation, responsible growth, and improving patients’ lives.
MEET OUR
Executive Leadership Team
MEET OUR
Board of Directors
MEET OUR
Scientific Advisory Board
Our history
Founded in 2005, Aquestive has spent two decades building a category-defining drug delivery platform with PharmFilm, earning the trust of patients, doctors, and shareholders through consistent innovation and execution.
2005
We are founded as MonoSol Rx LLC
and began development of the PharmFilm® technology
2006
We open our first manufacturing and development facility in Indiana
2010
We receive our first two FDA approvals
for Zuplenz® (ondansetron) oral soluble film and Suboxone® (buprenorphine and naloxone) sublingual film
2013
We begin research and development
for central nervous system (CNS) medicines
2016
We file Investigational New Drug Applications with the FDA
for Libervant®, Sympazan®, and Exservan®
2017
We officially become Aquestive Therapeutics, Inc.
2018
We become a publicly traded company on the NASDAQ: AQST
2019
We receive additional FDA-approvals
for Sympazam® (clobazam) oral film and Exservan® (riluzole) oral film
2020
Libervant® (diazepam) buccal film
New Drug Application accepted by the FDA
2025
Anaphylm™ (dibutepinephrine) sublingual film
New Drug Application accepted by the FDA
2005
We are founded as MonoSol Rx LLC
and began development of the PharmFilm® technology
2006
We open our first manufacturing and development facility in Indiana
2010
We receive our first two FDA approvals
for Zuplenz® (ondansetron) oral soluble film and Suboxone® (buprenorphine and naloxone) sublingual film
2013
We begin research and development
for central nervous system (CNS) medicines
2016
We file Investigational New Drug Applications with the FDA
for Libervant®, Sympazan®, and Exservan®
2017
We officially become Aquestive Therapeutics, Inc.
2018
We become a publicly traded company on the NASDAQ: AQST
2019
We receive additional FDA-approvals
for Sympazam® (clobazam) oral film and Exservan® (riluzole) oral film
2020
Libervant® (diazepam) buccal film
New Drug Application accepted by the FDA
2025
Anaphylm™ (dibutepinephrine) sublingual film
New Drug Application accepted by the FDA
Our responsibilities
Aquestive is committed to ethical conduct, environmental stewardship, and transparent corporate governance. We maintain high standards across compliance, marketing, and sustainability.
Our compliance program incorporates the elements of an effective compliance program in accordance with the “Compliance Program Guidance” for Pharmaceutical Manufacturers” (“OIG Guidance”) developed by the United States Department of Health and Human Services, Office of Inspector General (“OIG”) and our programs follow the PhRMA "Code Of Conduct When Interacting With Health Care Professionals."
Aquestive is a self funded employer, we comply with the Transparency in Coverage Act which requires us to provide a link to the machine readable files below.
This link leads to the machine readable files that are made available in response to the Federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers.
The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.
